HPV Vaccine Proves Its Mettle Free

By examining patient data in the TriNetX United States Collaborative Network, researchers have found that the human papillomavirus (HPV) vaccine effectively prevents the development of multiple HPV-related cancers in both males and females. The retrospective analysis included more than 1.7 million patients who had received the vaccine at least 5 years prior and age-matched controls. Notably, vaccinated men had a lower risk of developing head and neck cancers compared with their unvaccinated counterparts—2.8 and 6.3 cases per 100,000 patients, respectively. As in earlier studies, receiving the HPV vaccine also lowered the risk of developing cervical cancer compared with being unvaccinated—7.4 and 10.4 cases per 100,000 patients, respectively. The data, which were shared with media today, will be presented at the American Society of Clinical Oncology’s 2024 Annual Meeting, which starts on May 31.